(Lung Cancer) Ramucirumab + Pembrolizumab: What the Study Reported
(Lung Cancer) Ramucirumab + Pembrolizumab: What the Study Reported
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Ramucirumab + Pembrolizumab: What the Study Reported
- June 17, 2022
- 1 min read
On June 6, 2022, Karen L. Reckamp et al. from Cedars-Sinai Medical Center published results in the Journal of Clinical Oncology on the efficacy and safety of Ramucirumab + anti-PD-1 antibody in the Lung-MAP S1800A Phase II clinical trial for previously treated advanced non-small cell lung cancer patients with prior immune checkpoint inhibitor experience.
The Lung-MAP S1800A Phase II clinical trial randomized previously treated advanced non-small cell lung cancer patients with prior immune checkpoint inhibitor experience (N=136) into the Ramucirumab + anti-PD-1 antibody group (N=69) and the standard chemotherapy group (N=67). The primary endpoint was overall survival, and secondary endpoints included objective response rate and duration of response.
The trial results showed that the primary endpoint median overall survival was 14.5 months for the Ramucirumab + anti-PD-1 antibody group / 11.6 months for the standard chemotherapy group, with the Ramucirumab + anti-PD-1 antibody group showing a 31% reduction in death risk. The death risk for progression-free survival was reduced by 14%. The objective response rate was 22% for the Ramucirumab + anti-PD-1 antibody group / 28% for the standard chemotherapy group.
Regarding safety, the incidence of grade 3 or higher adverse events was 42% for the Ramucirumab + anti-PD-1 antibody group / 60% for the standard chemotherapy group.
Based on the Lung-MAP S1800A trial results, Karen L. Reckamp et al. stated that Ramucirumab + anti-PD-1 antibody therapy demonstrated improved overall survival compared with standard chemotherapy in previously treated advanced non-small cell lung cancer patients with prior immune checkpoint inhibitor experience, with a safety profile consistent with known data.
Source: https://ascopubs.org/doi/10.1200/JCO.22.00912
-
Investigational drug
-
Immunotherapy
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.